NewAmsterdam Pharma pany N.V.(NAMS) - 2022 Q4 - Annual Report

Exhibit 99.1 NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update — Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 — — Announced positive topline results from ROSE2 Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high- intensity statin therapy; plan to ...